COVID-19 is not a standard respiratory virus, it’s a serious threat to a number of vital organs. As medical specialists learn more about the virus and how it affects the human body, alarming complications are becoming evident including life-threatening blood clots in the lungs, heart and brain of COVID-19 patients.
Acute coronary syndromes research
Dr James Shaw is currently the Director of Education and Training in the Cardiology department. Whilst being an interventional Cardiologist Dr Shaw has participated in numerous research projects. Major areas of interest include: hyperlipidaemia.
Dr James Shaw is the Principle investigator in a number of trials that target the Acute Coronary Syndrome (ACS) population. Dr James Shaw provides patients that are an inpatient at Alfred Health an opportunity to participate in research that revolves around hyperlipidaemia. Projects that are in conjunction with pharmaceutical companies look at improving the treatment of reducing LDL levels and increasing HDL levels in a patient cholesterol profile, thus reducing future incidents in ACS events.
An example of a current project that Dr Shaw is a Principal investigator for is the Dal GenE trial. Screening patient that have recently experienced an ACS and that have the AA geneotype in the ADCY9 gene. This study is a double blinded study that is trialling the effects of a Drug known as Dalcetrapib. Other studies include AEGIS II, Compass, and Odyssey to name only a few.
Dr James Shaw is the Director of Education and Training in Cardiology, and has held this position since 2014.